Related references
Note: Only part of the references are listed.Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma
Ivano Riva et al.
JOURNAL OF GLAUCOMA (2014)
Level of agreement among Latin American glaucoma subspecialists on the diagnosis and treatment of glaucoma: results of an online survey
Daniel E. Grigera et al.
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (2013)
Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma
Martina Tomic et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication
Sudipta Ghosh et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2012)
Definition of glaucoma: clinical and experimental concepts
Robert J. Casson et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2012)
Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma
Stefano Gandolfi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2012)
Long-term Effect of BAK-free Travoprost on Ocular Surface and Intraocular Pressure in Glaucoma Patients After Transition From Latanoprost
Makoto Aihara et al.
JOURNAL OF GLAUCOMA (2012)
Comparative In Vitro Toxicology Study of Travoprost Polyquad-preserved, Travoprost BAK-preserved, and Latanoprost BAK-preserved Ophthalmic Solutions on Human Conjunctival Epithelial Cells
Francoise Brignole-Baudouin et al.
CURRENT EYE RESEARCH (2011)
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy
Y. Kitazawa et al.
EYE (2011)
Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review
Gregory Reardon et al.
PATIENT PREFERENCE AND ADHERENCE (2011)
Ocular preservatives: associated risks and newer options
Indu Pal Kaur et al.
CUTANEOUS AND OCULAR TOXICOLOGY (2009)
Pharmacological management of primary open-angle glaucoma - Second-line options and beyond
Carroll A. B. Webers et al.
DRUGS & AGING (2008)
Efficacy and Tolerability of Prostaglandin Analogs A Meta-analysis of Randomized Controlled Clinical Trials
Florent Aptel et al.
JOURNAL OF GLAUCOMA (2008)
Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure
Carol B. Toris et al.
JOURNAL OF GLAUCOMA (2007)
Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma
Hannu Uusitalo et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2006)
The number of people with glaucoma worldwide in 2010 and 2020
HA Quigley et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2006)
Intraocular pressure-lowering effects of all commonly used glaucoma drugs - A meta-analysis of randomized clinical trials
R van der Valk et al.
OPHTHALMOLOGY (2005)
In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells
JM Guenoun et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study
RK Parrish et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2003)
Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication
PJ Pisella et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2002)
Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients
A Waldock et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2000)
Share Paper
